top of page


Friday, March 22, 2024

10:00-12:00      Vendor Setup


11:00-12:00      Attendee Check-in (Columbia Ballroom)

Badge and tram ticket provided at check-in

12:00-1:00        Lunch/Product Theater Presentation by Sanofi

New Era, New Data:  The Evolving Story of Kevzara (sarilumab)

Orrin Troum, MD


1:00-1:15          Breaks/Exhibits


1:15-2:15          Session 1:  Rheumatology Clinical Pearls  

 Angus Worthing, MD 

2:15-2:30          Break/Exhibits


2:30-3:30          Session 2:  Innovations in Rheumatology

 Alvin Wells, MD

3:30-4:40          Product Theater Presentation by Alexion Rare Disease

Get Straight to the source of Hypophosphatasia (HPP)

Alvin Wells, MD

5:30-8:30          Opening Remarks and Welcome Dinner at Seven Glaciers


Saturday, March 23, 2024

8:00-9:00         Breakfast/Product Theater Presentation by Novartis

COSENTYX®(secukinumab) Cases: An Interactive Game-Based Challenge About Psoriatic Arthritis, Ankylosing Spondylitis, and Enthesitis-Related Arthritis

Stan Read, Associate Director, Thought Leader Liaison

9:00-10:00       Session 3:  Rheumatology Advocacy Update for Alaska 

 Angus Worthing, MD 

10:00-10:30     Break/Exhibits

10:30-11:30     Session 4:  PsA Update

Arthur Kavanaugh, MD

11:30-12:00      Break/Exhibits/Hotel Checkout

12:00-1:00       Lunch/Product Theater Presentation by AbbVie

TNFI Nonresponders An Engaging Discussion on Efficacy and Safety in the Treatment of RA

Sanjay Chabra, DO

1:00-2:00          Session 5:  Use of Clinical Measures to Treat RA

Martin Bergman, MD 

2:00-2:30          Break/Exhibits

2:30-3:30          Session 6:  Pediatric Rheumatology for the Adult Rheumatologist

Kabita Nanda, MD

3:30-4:00          Break/Exhibits


4:00-5:00          Session 7:  Emerging Therapeutics in Systemic Lupus Erythematosus (SLE)

Yael "Ellie" Klionsky, MD

5:30-7:00      Closeout Reception for Learning Attendees** - Sponsored by Sanofi

**In Columbia Ballroom Foyer

Sunday, March 24, 2024

8:00-9:00         Breakfast/Product Theater Presentation by AstraZeneca

SAPHNELO® (anifrolumab-fnia): A First-In-Class IFN-1 Signaling Inhibitor, Now With 4-Year Data From a Long-Term Safety and Tolerability Study

Leanna Wise, MD

9:00-10:00       Session 8:  Update on JAK inhibitors for Rheumatoid Arthritis

 Orrin Troum, MD 

10:00-10:30    Closing Comments

bottom of page